About: Werewolf Therapeutics, Inc., a biopharmaceutical company, engages in the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. The company designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies through its proprietary PREDATOR platform. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; WTX-921, a conditionally activated IL-10 INDUKINE molecule for the treatment of inflammatory bowel disease and potentially other inflammatory diseases; and WTX-712, an activated Interleukin-21(IL-21) and WTX-518, an activated IL-18 (IL-18) INDUKINE molecule for the treatment of cancer. In addition, it develops WTX-1011, a conditionally activated INDUCER T cell engager molecule that targets STEAP 1 for prostate cancer, as well as WTX-2022 that targets CDH6 for ovarian and kidney cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts.
Sector: Healthcare
Industry: Biotechnology
Latest price: $1.06 (+1.92%)
HOWL NASDAQ Werewolf Therapeutics Inc
Werewolf Therapeutics Inc share price
HOWL price activity
Last Price
$1.060
Change (24hr)
0.02 USD (1.92%)
Volume
388.39K
Volume (4w avg)
-
Open
$1.03
Day Range
$1.02 - $1.08
Previous Close
$1.04
Last Trade
28 Oct, 8:11 pm GMT+0
Delayed
28 Oct, 8:11 pm GMT+0
HOWL price performance
Delayed
28 Oct, 8:11 pm GMT+0
HOWL Market Signals